Gerald Falchook

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (10)

Suresh Ramalingam

Professor, Director of Medical Oncology

Emory University

UNITED STATES

View details

Scott Tykodi

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Ganesh Mugundu

VP, Head of Early Clinical Development

UNITED STATES

View details

Jonathan W. Goldman

Associate Professor

UCLA

UNITED STATES

View details

Louise Carter

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM

View details

Susanna Ulahannan

Assistant Professor

UNITED STATES

View details

Suzanne Jones

UNITED STATES

View details

Jennifer Choe

Vanderbilt University

UNITED STATES

View details

BABAR BASHIR

Assistant Professor

Thomas Jefferson University

UNITED STATES

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gerald Falchook

Research Interests

Explore related searches

Contact this professor

Articles (13)

TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy

Impact of Food and Drug Administration Project Optimus Guidance on Design of Early-Phase Clinical Trials

Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers

4-1BB Antibodies in Oncology Clinical Trials: A Review

B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors

Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors

T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer

Collaborators (10)

Suresh Ramalingam

Scott Tykodi

Ganesh Mugundu

Jonathan W. Goldman

Louise Carter

Susanna Ulahannan

Suzanne Jones

Jennifer Choe

BABAR BASHIR

Timothy Yap

Make your next move.